
Viruses | Issue Cover Articles in the First Half of 2026

1. “Screening of the Pandemic Response Box Library Identified CRM1/XPO1 as an Anti-Mammarenavirus Druggable Target”
by Chukwudi A. Ofodile, Beatrice Cubitt, Ngozi Onyemelukwe, Chetachi B. Okwuanaso, Haydar Witwit and Juan C. de la Torre
Viruses 2026, 18(1), 103; https://doi.org/10.3390/v18010103
Available online: https://www.mdpi.com/1999-4915/18/1/103
Cover Story: Several MaAv can cause severe, often fatal hemorrhagic fevers in humans following zoonotic transmissions. Lassa and Junín viruses remain major regional public health threats, while the globally distributed lymphocytic choriomeningitis virus is an underappreciated human pathogen of clinical significance. Despite this burden, no MaAv FDA-approved vaccines or antivirals exist. We screened the Pandemic Response Box and identified three potent inhibitors of MaAv replication: the Tat protein antagonist Ro-24-7429, a pirolazamide-based DHODH inhibitor, and verdinexor, a selective inhibitor of nuclear export targeting XPO1/CRM1. Notably, verdinexor displayed striking antiviral synergy in combination with Ro-24-7429 or the picolinamide-based DHODH inhibitor. Our findings highlight host-directed nuclear export inhibition as a promising strategy for combination therapy against pathogenic MaAv.

2. “Prolyl tRNA Synthetase Is Required for Mammarenavirus Multiplication”
by Haydar Witwit, Pablo Aparicio Ibanez, Ruifeng Zhou, Nathaniel Jackson, Ruby Escobedo, Beatrice Cubitt, Roaa Khafaji, Rachel Y. Sattler, Luis Martinez-Sobrido and Juan Carlos de la Torre
Viruses 2026, 18(2), 202; https://doi.org/10.3390/v18020202
Available online: https://www.mdpi.com/1999-4915/18/2/202
Cover Story: Mammarenaviruses include highly deadly pathogens such as Lassa and Junín viruses, for which no FDA‑approved vaccines or antivirals exist. We show that the host enzyme prolyl tRNA synthetase (PRS), a domain of the bifunctional glutamyl‑prolyl tRNA synthetase (EPRS1), is essential for mammarenavirus multiplication. The PRS inhibitor halofuginone potently inhibits mammarenavirus multiplication in infected cells by disrupting prolyl-tRNA charging, depriving proline-rich viral proteins, and severely impairing viral assembly and budding. These results support PRS as a druggable target for the development of host-direct antivirals to combat human pathogenic mammarenaviruses.

3. “Host Cell Central Carbon Metabolism and Cellular NAD+ Pool Regulate Efficient Replication of Vesicular Stomatitis Virus”
by Kush K. Pandey, Bikash R. Sahoo, D. S. McVey and Asit K. Pattnaik
Viruses 2026, 18(3), 326; https://doi.org/10.3390/v18030326
Available online: https://www.mdpi.com/1999-4915/18/3/326
Cover Story: Vesicular stomatitis virus (VSV) is a promising oncolytic virus whose replication is tightly linked to host cell metabolism. In cancer cells, such as glioblastoma, metabolic pathways including glycolysis, the pentose phosphate pathway (PPP), and glutaminolysis are extensively rewired to support growth and survival. Here, we demonstrate that VSV replication critically depends on glycolytic flux, glutamine metabolism, and intracellular NAD+ availability. Pharmacological inhibition of these pathways suppresses viral replication, while restoration of NAD+ rescues viral growth. Notably, depletion of G6PD enhances replication, revealing complex metabolic regulation. These findings highlight a redox-centric framework governing VSV replication and provide insights for optimizing oncolytic virotherapy through metabolic targeting.

4. “The 4.4 Å Capsid Structure of the Giant Melbournevirus Belonging to the Marseilleviridae Family”
by Raymond N. Burton-Smith, Chantal Abergel, Kenta Okamoto and Kazuyoshi Murata
Viruses 2026, 18(4), 433; https://doi.org/10.3390/v18040433
Available online: https://www.mdpi.com/1999-4915/18/4/433
Cover Story: Giant viruses have complex capsids. The cryo-EM structure of Melbournevirus reveals its organization and assembly. Using advanced reconstruction, the capsid reached 4.9 Å (global) and 4.42 Å (local) resolution, showing that large (~250 nm) viruses can be resolved with limited data. The major capsid protein (MCP) forms a conserved double jelly roll trimers with a unique cup-like structure binding a cap protein. Five-fold vertices contain a pentameric penton base, with underlying densities linking to internal membranes. A minor capsid protein network (Glue, Zipper, Cement, Lattice) stabilizes the shell, while Scaffold proteins connect to membranes and may replace tape-measure proteins in controlling size. MCP trimers follow a “golf club” motif, aiding curvature. Overall, conserved MCP architecture coexists with flexible assembly strategies.

5. “Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication”
by Collins Oduor Owino, Balakrishnan Chakrapani Narmada, Gian Yi Lin, Pauline Poh Kim Aw, Nivrithi Ganesh, Jovi Tan Siying, Marie-Laure Plissonnier, Thangavelu Thangavelu Matan, Niranjan Shirgaonkar, Pablo Bifani et al.
Viruses 2026, 18(5), 545; https://doi.org/10.3390/v18050545
Available online: https://www.mdpi.com/1999-4915/18/5/545
Cover Story: Chronic hepatitis b (CHB) remains a global health challenge, especially in areas with high prevalence. HBV, like other viruses, depends on human host factors and processes to establish an efficient infection. Identifying host cellular factors that support or restrict HBV infection is essential for understanding the molecular basis of CHB infection and developing host-targeting therapies. Here, we identify cyclin L1 (CCNL1) as a host susceptibility factor for HBV. Knockdown of CCNL1 reduces HBV transcripts and decreases binding of the total RNAPII, phospho-RNAPII Ser2/Ser5, and histone marks (H3ac and H3K27ac) on cccDNA, resulting in impaired viral cccDNA-dependent transcription. Moreover, CCNL1 expression is elevated in chronic hepatitis b patients’ livers compared to those with resolved infection, underscoring its association with CHB.

6. “Mapping the TAR vRNA Interaction with HIV-1 Integrase”
by Jian Sun, Rahul Yadav, Tolga Catmakas, Luke Fisher, Nicholas C. Fitzkee and Jacques J. Kessl
Viruses 2026, 18(6), 657; https://doi.org/10.3390/v18060657
Available online: https://www.mdpi.com/1999-4915/18/6/657
Cover Story: The Integrase protein (IN) of Human Immunodeficiency Virus type 1 (HIV-1) inserts the reverse-transcribed viral DNA (vDNA) into the host chromosome. Previous observations have shown that IN not only directs vDNA integration but also contributes to the maturation step during viral egress. We and others have previously reported a strong interaction between the viral RNA (vRNA) and HIV-1 IN required for correct virion morphology. In this study, we conducted a comprehensive mapping of this IN–vRNA interaction using both vRNA crosslinking and NMR methodologies. These approaches identified functionally essential contact points between the vRNA and IN.